BriaCell Therapeutics (BCT) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Key Stats

• Today's Range: C$10.60 to C$11.07
• 50-Day Range: C$10.60 to C$10.60
• 52-Week Range: C$3.50 to C$15.75
• Volume: 3,402 shs
• Average Volume: 12,671 shs
• Market Capitalization: C$168.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$15.00
• Consensus Rating: N/A

BCT Stock Analysis - Frequently Asked Questions

How have BCT shares performed this year?

BriaCell Therapeutics' stock was trading at C$10.60 at the beginning of the year. Since then, BCT shares have increased by 0.0% and is now trading at C$10.60.
View the best growth stocks for 2025 here.

How do I buy shares of BriaCell Therapeutics?

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of BriaCell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), BMO MSCI India ESG Leaders Index ETF (ZID), Athersys (ATHX), Anavex Life Sciences (AVXL), Gene Biotherapeutics (CRXM) and Inovio Pharmaceuticals (INO).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:BCT
• CIK: N/A
• Web: www.briacell.com
• Phone: +1-604-9211810
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$15.00
• High Stock Price Target: C$15.00
• Low Stock Price Target: C$15.00
• Potential Upside/Downside: +41.5%
• Consensus Rating: N/A
• Rating Score (0-4): 0.00
• Research Coverage: 0 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 129.63
• Quick Ratio: 128.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$3.34 per share
• Price / Cash Flow: 3.17
• Book Value: C$3.60 per share
• Price / Book: 2.94

Miscellaneous

• Outstanding Shares: 15,913,000
• Free Float: N/A
• Market Cap: C$168.68 million
• Optionable: Not Optionable
• Beta: N/A